Novo Nordisk weight-loss drug wins US approval as a daily pill
Shares in Danish company rise as drugmaker secures lead in oral obesity treatment
Related reading
Eli Lilly wins US approval for weight-loss drug in pill form
New drug Foundayo sets up battle with Novo Nordisk for oral obesity drugs
Novo Nordisk shares drop 15% after poor trial results for new obesity drug
Once-a-week injection achieved less weight loss than rival treatment
Battle for weight-loss supremacy shifts from jabs to pills
Novo Nordisk’s Wegovy tablet offers Danish drugmaker window to win back market share from Eli Lilly
New Novo Nordisk drug could beat market leaders for weight loss, early results…
Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose
Novo Nordisk loses further ground in obesity market
Danish drugmaker expects sales and profit growth at lower end of its guidance this year
Novo Nordisk calls for US import ban on key ingredient for obesity drug copycats
Danish group loses share in diabetes drugs to rivals, with first-half sales growth easing to 8%